Tweets
Is it time to go back to big F2F conferences? Yes if you get VAX'd, Carded & Temp'd AND you Mask-up, Back-up and Wash-up! It might could be safe! https://t.co/Ut6LxAEmiT
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Filgotinib (Jyseleca) was approved by European Commission approved for EU use in adults with moderately to severely active Ulcerative colitis (not responding to conventional therapy or a biologic). Rec based on Phase 2b/3 SELECTION trial. https://t.co/vMGNMKhy34
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Improving Our Everyday RA Practice: Dr. David Liew ( @drdavidliew) discusses abstracts #0830 and #0815 presented at the #ACR21 annual meeting.
https://t.co/63oTD80hrD https://t.co/iQPVYWoIuF
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Perspectives on CV safety: JAK inhibitor (Tofacitinib) and TNF inhibitors
https://t.co/yBnIsgU62y https://t.co/zT1PM08wjN
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
More severe COVID-19 outcomes in African American, Hispanic individuals with SLE
https://t.co/ZHmj5wXEtS https://t.co/c88a0y2i7K
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Treat to Target in SLE: Dr. Yuzaiful Yusof ( @Yuz6Yusof) reviews abstract #0865 presented at the #ACR21 annual meeting.
https://t.co/srdhzwlvPF https://t.co/8pbb5LeFtY
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Health Disparities: Dr. Arthur Kavanaugh discussed how a number of studies presented at the #ACR21 annual meeting are looking at the impact of socioeconomic factors and race on outcomes.
https://t.co/KunXNfbaRk https://t.co/b8SgnXmrZO
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Potpourri of Biosimilar Trials: Dr. Jonathan Kay discusses a number of biosimilar trials presented at the #ACR21 annual meeting, including abstracts #0822, #0820, #0817 and #0823.
https://t.co/aQXrKKZXhb https://t.co/4Bn7rvogHY
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Updates on New Treatments for SpA: Drs. Antoni Chan ( @synovialjoints) interviews Dr. Laura Coates discuss a number of studies related to new treatments for SpA presented at the #ACR21 annual meeting.
https://t.co/mOutSekQkJ https://t.co/JG18q9PsdD
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Best of PSA from Sunday Sessions: Dr. Rachel Tate ( @uptoTate) discusses the RheumNow PSA faculty's best PsA abstracts from Sunday sessions, including abstracts #0750 and #0944, which were presented at the #ACR21 annual meeting.
https://t.co/wgMq2rsWNj https://t.co/Z2By90rBEy
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Lipidomic Differences in PsA and RA: Dr. Pedro Castillo ( @_Castillo_Pedro) discusses abstract #0946 presented at the #ACR21 annual meeting.
https://t.co/M8O1OdvFAk https://t.co/4QMgXPhLzn
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
Hydroxychloroquine Levels in Type I and 2 Lupus: Bella Mehta ( @bella_mehta) interviews Dr. Megan Clowse about abstract #0877, presented at the #ACR21 annual meeting.
https://t.co/L62iO8J9QF https://t.co/Oy58jbPPts
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 8 months ago
